|
Name |
Neochlorogenic acid
|
Molecular Formula | C16H18O9 | |
IUPAC Name* |
(1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
|
|
SMILES |
C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
|
|
InChI |
InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14+,16-/m1/s1
|
|
InChIKey |
CWVRJTMFETXNAD-NXLLHMKUSA-N
|
|
Synonyms |
Neochlorogenic acid; 906-33-2; 5-O-Caffeoylquinic acid; Neochlorogenate; Nochlorogenic acid; CHEBI:16384; trans-Neochlorogenic acid; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid; 5-O-(trans-3,4-Dihydroxycinnamoyl)-D-quinic acid; CHEMBL249450; O4601UER1Z; trans-5-O-caffeoyl-D-quinic acid; trans-5-O-Caffeoylquinic acid; 5-Caffeoylquinic acid; caffeoylquinic acid; trans-5-O-caffeoyl-D-quinate; (1R,3R,4S,5R)-3-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; 1D-[1(OH),3,4/5]-3-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; 5-Caffeylquinic acid; 5-O-caffeoyl quinic acid; 3-CQA; (E)-Neochlorogenic Acid; UNII-O4601UER1Z; Neochlorogenic-acid; EINECS 212-997-1; MFCD10566639; Quinic acid, 5-caffeoyl-, E-; SCHEMBL13567302; SCHEMBL18317299; ACon1_000392; DTXSID301347903; HMS3886H18; HY-N0722; ZINC4096248; 3-O-(E)-CAFFEOYLQUINIC ACID; BDBM50163308; s9136; AKOS015901853; AC-6061; CCG-268077; CS-3770; Neochlorogenic acid, analytical standard; NCGC00169121-01; NCGC00169121-02; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexanecarboxylic acid; AS-75008; Cyclohexanecarboxylic acid, 3-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,4,5-trihydroxy-, (1R-(1alpha,3alpha,4alpha,5beta))-; N1155; C17147; 906N332; Q-100887; Q6992128; 656B3E48-4F1F-4FC8-A3B2-B0FADAB84AF5; Neochlorogenic acid, from Lonicera japonica, >=98.0% (HPLC); NEOCHLOROGENIC ACID (CONSTITUENT OF ST. JOHN'S WORT) [DSC]; (1R,3R,4S,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid; (1R-(1.ALPHA.,3.ALPHA.,4.ALPHA.,5.BETA.))-3-((3-(3,4-DIHYDROXYPHENYL)-1-OXOALLYL)OXY)-1,4,5-TRIHYDROXYCYCLOHEXANECARBOXYLIC ACID; (1R-(1alpha,3alpha,4alpha,5beta))-3-((3-(3,4-Dihydroxyphenyl)-1-oxoallyl)oxy)-1,4,5-trihydroxycyclohexanecarboxylic acid; 1,3beta,4alpha-Trihydroxy-5alpha-(3,4-dihydroxycinnamoyloxy)cyclohexane-1beta-carboxylic acid; 342811-68-1; CYCLOHEXANECARBOXYLIC ACID, 3-(((2E)-3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)OXY)-1,4,5-TRIHYDROXY-, (1R,3R,4S,5R)-; CYCLOHEXANECARBOXYLIC ACID, 3-((3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPENYL)OXY)-1,4,5-TRIHYDROXY-, (1R-(1.ALPHA.,3.ALPHA.(E),4.ALPHA.,5.BETA.))-; CYCLOHEXANECARBOXYLIC ACID, 3-((3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPENYL)OXY)-1,4,5-TRIHYDROXY-, (1R-(1.ALPHA.,3.ALPHA.,4.ALPHA.,5.BETA.))-; Cyclohexanecarboxylic acid,3-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-,(1R,3R,4S,5R)-; NCGC00169121-02!(1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
|
|
CAS | 906-33-2 | |
PubChem CID | 5280633 | |
ChEMBL ID | CHEMBL249450 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 354.31 | ALogp: | -0.4 |
HBD: | 6 | HBA: | 9 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 165.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 25 | QED Weighted: | 0.244 |
Caco-2 Permeability: | -6.31 | MDCK Permeability: | 0.00001790 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.959 |
Human Intestinal Absorption (HIA): | 0.763 | 20% Bioavailability (F20%): | 0.955 |
30% Bioavailability (F30%): | 0.997 |
Blood-Brain-Barrier Penetration (BBB): | 0.231 | Plasma Protein Binding (PPB): | 79.94% |
Volume Distribution (VD): | 0.312 | Fu: | 19.57% |
CYP1A2-inhibitor: | 0.143 | CYP1A2-substrate: | 0.021 |
CYP2C19-inhibitor: | 0.029 | CYP2C19-substrate: | 0.05 |
CYP2C9-inhibitor: | 0.041 | CYP2C9-substrate: | 0.418 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.141 |
CYP3A4-inhibitor: | 0.051 | CYP3A4-substrate: | 0.027 |
Clearance (CL): | 2.131 | Half-life (T1/2): | 0.888 |
hERG Blockers: | 0.037 | Human Hepatotoxicity (H-HT): | 0.139 |
Drug-inuced Liver Injury (DILI): | 0.409 | AMES Toxicity: | 0.034 |
Rat Oral Acute Toxicity: | 0.031 | Maximum Recommended Daily Dose: | 0.019 |
Skin Sensitization: | 0.589 | Carcinogencity: | 0.164 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.103 |
Respiratory Toxicity: | 0.039 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001471 | 1.000 | D0KN2M | 0.570 | ||||
ENC001917 | 0.811 | D0V9EN | 0.457 | ||||
ENC001440 | 0.457 | D0I3RO | 0.293 | ||||
ENC001579 | 0.408 | D08HVR | 0.284 | ||||
ENC002582 | 0.373 | D0BA6T | 0.277 | ||||
ENC001101 | 0.346 | D0P7JZ | 0.267 | ||||
ENC004024 | 0.345 | D0U0OT | 0.259 | ||||
ENC002823 | 0.323 | D00KRE | 0.245 | ||||
ENC000002 | 0.315 | D0Y6KO | 0.242 | ||||
ENC004911 | 0.313 | D0E6OC | 0.241 |